Larkspur Health Acquisition Corp. (NASDAQ: LSPR) operates as a blank check special purpose acquisition company focused on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, primarily targeting the biotechnology sector in the United States; it currently conducts no significant independent operations. Founded in 2021 and headquartered in Bridgewater, New Jersey, the company offers no core products or services beyond its SPAC structure and sponsor support from Larkspur Health LLC. In December 2022, Larkspur completed a reverse merger business combination with ZyVersa Therapeutics, Inc., a clinical-stage biopharmaceutical firm developing therapies for renal and inflammatory diseases including VAR 200 and IC 100; post-merger, the combined entity was renamed ZyVersa Therapeutics, Inc. and began trading under the ticker ZVSA, with Larkspur's LSPR shares marked inactive or delisted thereafter. The transaction included approximately $10 million in committed financing via PIPE investments and interim funding to support ZyVersa's clinical programs, though nearly 99% of Larkspur shares were redeemed prior to closing. As of late 2025, LSPR trades sporadically at depressed levels around $7-22 with high volatility and no active operations reported.